400 Farmington Avenue
Farmington, CT 06030
AlloStem Therapeutics is a privately held pharmaceutical company committed to helping cancer patients by the discovery and development of targeted therapies. Allostem’s primary interest lies in the inhibition of targets associated with the Ras pathway. AlloStem has discovered a novel class of MEK kinase inhibitors that improve the biopharmaceutical properties of previous MEK inhibitors. Allostem’s clinical candidate, CIP-1374, is an allosteric MEK kinase inhibitor that combines potent activity against MEK1/2 kinase and against chemo-resistant ovarian cancer stem cells.
For more information, please visit www.allostem.com